Women Often Opt Out of Lung Cancer Studies
Posted on: Thursday, 22 December 2005, 11:15 CST
By Megan Rauscher
NEW YORK (Reuters Health) - Women and African-Americans are under-represented in lung cancer clinical trials, clinicians report in the journal Cancer. "The lack of participation by minorities and women shut them out of the next generation of potentially life-saving treatment," warned Dr. Wei Du in comments to Reuters Health.
"It also makes it all the more difficult for clinicians to translate treatment benefits and risks found in a clinical trial to these under-represented patient populations," the researcher added.
Du, from Wayne State University in Detroit, and colleagues reviewed the medical records of 427 lung cancer patients who were eligible to participate in lung cancer clinical trials at Detroit's Karmanos Cancer Institute between 1994 and 1996. The group comprised 175 African-Americans and 252 from other races and 59 percent were male.
Overall, only 91 patients (21 percent) chose to participate in a lung cancer treatment trial.
Patients opting out of a trial were more likely to be African-American (45 percent) compared with those who chose to enroll (25 percent). Non-enrollees were also more likely to be female (43 percent) than enrollees (32 percent), and older than 70 years of age (24 percent vs 10 percent).
"Our finding," concludes Du, "supports the need for better patient education and new recruitment strategies targeting these specific patient subgroups to help ensure equal representation of women and minority groups in cancer clinical trials."
SOURCE: Cancer January 15, 2005.
Source: REUTERS
Related Articles
- Study Finds Delay In Follow-Up Among African-American Women Receiving Abnormal Breast Finding
- New Study Reveals Radiation Treatment Less Likely for African American Women Fighting Breast Cancer
- Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
- AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer By 2016
- TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
- CoAxia(TM) Announces FDA Approval of Clinical Trial for Its Novel Stroke Treatment in Patients Up to 24 Hours After Onset
- Study looks at factors influencing African-American women's decisions to join cancer screening trial
- Vitamin D Deficiency: A Hidden Health Epidemic Among African-American Women
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
- Risk Factors for Urinary Incontinence in African-American Women
 |
 |
User Comments (0)
RSS Feeds